Engineered immune cells take aim at childhood cancer

NCT ID NCT07502287

Recruiting now Disease control Sponsor: Beijing Biotech Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment for children and young adults with neuroblastoma that has returned or not responded to standard care. The treatment uses specially engineered immune cells from donated cord blood that are designed to recognize and attack two different markers on the cancer cells. Participants receive chemotherapy first to prepare their immune system, then the engineered cells are given intravenously. The study aims to find the safest dose and see if the treatment can shrink tumors or slow the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: engineered immune cells (CAR-NK cells) that target two proteins on cancer cells
What this could lead to: If it works, this could offer a new treatment option for children with neuroblastoma that has come back or not responded to other therapies.
What could go wrong: This is an early-phase trial with only 36 participants, so it may not work for everyone. There are risks of side effects like immune reactions or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GANGLIONEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ganglioneuroblastoma neuroblastoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GANGLIONEUROBLASTOMA HIGH-RISK NEUROBLASTOMA REFRACTORY NEUROBLASTOMA RELAPSED NEUROBLASTOMA

Contacts and locations

Locations

Peking University Shenzhen Hospital
RECRUITING

Shenzhen, Guangdong, 518036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.